Stacey E. Tarvin

Pediatric Rheumatology

699 Riley Hospital Dr Rm 307
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+-Year Results From a Multicenter, Open-Label Study.

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+-Year Results From a Multicenter, Open-Label Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 28, 2026

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 28, 2026

Demographic and disease representativeness of Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry participants with lupus: a single center retrospective cohort.

Demographic and disease representativeness of Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry participants with lupus: a single center retrospective cohort.

Journal: Pediatric rheumatology online journal

Published: November 14, 2025

Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Pediatric Patients: An ARChiVe Study.

Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Pediatric Patients: An ARChiVe Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: September 24, 2025

Development and validation of a multi-institutional electronic juvenile idiopathic arthritis phenotype.

Development and validation of a multi-institutional electronic juvenile idiopathic arthritis phenotype.

Journal: Seminars in arthritis and rheumatism

Published: August 07, 2025

Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.

Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.

Journal: Annals of the rheumatic diseases

Published: March 07, 2025

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.

Journal: Rheumatology (Oxford, England)

Published: November 04, 2024

Experiences of sexual and reproductive health screening and counseling in the clinical setting among adolescents and young adults with rheumatic disease.

Experiences of sexual and reproductive health screening and counseling in the clinical setting among adolescents and young adults with rheumatic disease.

Journal: Pediatric rheumatology online journal

Published: November 01, 2024

Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.

Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.

Journal: Clinical and experimental rheumatology

Published: October 31, 2024

Telemedicine for the Care of Patients with Idiopathic Inflammatory Myopathies: Experience, Insights and Future Directions from the International Myositis Assessment and Clinical Studies Telemedicine Scientific Interest Group.

Telemedicine for the Care of Patients with Idiopathic Inflammatory Myopathies: Experience, Insights and Future Directions from the International Myositis Assessment and Clinical Studies Telemedicine Scientific Interest Group.

Journal: Current rheumatology reports

Published: August 02, 2024

Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome.

Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 04, 2024

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.

Journal: Arthritis care & research

Published: March 27, 2024

Showing 1-12 of 22

Last Updated: 09/26/2026